Images in Immunotherapy and Precision Oncology: Angiosarcoma of the Spleen and Liver

Authors

Anagha Deshpande
Javier Munoz
Katalin Kelemen
Vrushali Dabak, Henry Ford HealthFollow
Amr Hanbali
Razelle Kurzrock

Recommended Citation

Deshpande A, Munoz J, Kelemen K, Dabak V, Hanbali A, and Kurzrock R. Images in Immunotherapy and Precision Oncology: Angiosarcoma of the Spleen and Liver. J Immunother Precis Oncol 2023; 6(1):56-58.

Document Type

Article

Publication Date

2-1-2023

Publication Title

J Immunother Precis Oncol

Abstract

Primary splenic or hepatic angiosarcomas are ultra-rare and aggressive malignancies associated with poor prognosis. The mainstay treatments are surgical resection and chemotherapy. We report a case of angiosarcoma in a 50-year-old woman who presented with bruising, fatigue, ecchymosis, and hepatosplenomegaly. She was treated with the multi-kinase inhibitor sunitinib for 4 weeks before developing a splenic hemorrhage and succumbing. Recent studies have demonstrated the clinical benefit of immunotherapies in angiosarcomas. Additionally, sequencing techniques have showcased the diverse molecular aberrations involved in angiosarcomas, which offer opportunities for precision-matched targeted therapies such as inhibitors of the VEGF/VEGFR axis and PI3K/Akt/mTor pathway.

PubMed ID

36751660

Volume

6

Issue

1

First Page

56

Last Page

58